Frederic Kinkead

Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line

Introduction:Ibrutinib and acalabrutinib are both Bruton‚Äôs tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Since st...

Bruno Emond , MA;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

Xiaoxiao Lu ;

Frederic Kinkead ;

Wasiulla Khan ;

Patrick Lefebvre , MA;

Linda Wu ;

Zaina P. Qureshi ;

Ryan Jacobs ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Frederic Kinkead

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products